<h1>Pharma firm approves slump sale of environmental solutions business to subsidiary effective October 1, 2025, transferring operations and assets</h1> A pharmaceutical manufacturer's board approved a slump sale of its environmental solutions business to a wholly owned subsidiary effective 1 October 2025, transferring operations and assets relating to waste management, water and wastewater treatment, bioremediation, pollution control and related plant services. The transaction restructures the business into a dedicated subsidiary to enable focused management and growth. Legally, the deal is a transfer of undertaking on a slump-sale basis that will trigger corporate approvals, securities disclosure obligations, transfer of contracts and employees, applicable tax consequences and regulatory consents for environmental and operational licences. Forward-looking statements accompany the announcement.